Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (OPTION)
Open-label, Uncontrolled, Prospective Long-term Observation of Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years
Sponsor: Bayer
A observational or N/A phase clinical study on Pulmonary Hypertension, this trial is completed. The trial is conducted by Bayer and has accumulated 14 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
May 2019 — Jan 2021 [monthly]
Completed
▶ Show 9 earlier versions
-
Aug 2018 — May 2019 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jul 2018 — Aug 2018 [monthly]
Active Not Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Jul 2017 — Dec 2017 [monthly]
Active Not Recruiting NA
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting NA
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
For direct contact, visit the study record on ClinicalTrials.gov .